Cowen downgraded Regulus Therapeutics (NASDAQ: RGLS) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Regulus Therapeutics click here. For more ratings news on Regulus Therapeutics click here.

Shares of Regulus Therapeutics closed at $2.80 yesterday.